Tocagen

TOCA NASDAQ
4.520
+0.160
+3.67%
After Hours: 4.520 0 0.00% 17:00 08/16 EDT
Open
4.380
Prev Close
4.360
High
4.540
Low
4.180
Volume
265.24K
Avg Vol (3M)
343.34K
52 Week High
15.80
52 Week Low
4.120
% Turnover
1.11%
Market Cap
108.02M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Tocagen TOCA stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Tocagen Inc. (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells. Its lead product candidates are vocimagene amiretrorepvec (Toca 511) and flucytosine extended release (Toca FC). Toca 511 is an investigational injectable retroviral replicating vector (RRV) that encodes a prodrug activator enzyme, cytosine deaminase (CD). Toca FC is an investigational extended-release version of 5-fluorocytosine (5-FC), a prodrug that is inactive as an anti-cancer drug. As of February, 2017, Tocagen has completed enrollment of the Phase II portion with 187 patients.
MORE >

Recently

Name
Price
%Change